Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2011

01-09-2011

Preventive care in prostate cancer patients: following diagnosis and for five-year survivors

Authors: Claire F. Snyder, Kevin D. Frick, Robert J. Herbert, Amanda L. Blackford, Bridget A. Neville, Michael A. Carducci, Craig C. Earle

Published in: Journal of Cancer Survivorship | Issue 3/2011

Login to get access

Abstract

Introduction

Prostate cancer is the most common male cancer. Survival rates are high, making preventive care maintenance important. Factors associated with prostate-cancer cases’ preventive care in the short-term (Year 1) and long-term (Year 5), and how survivors’ care compares to non-cancer controls, require study.

Methods

This retrospective, controlled SEER-Medicare study included loco-regional prostate cancer cases age ≥66 in fee-for-service Medicare diagnosed in 2000 and surviving ≥12 months, and non-cancer controls matched to cases on socio-demographics and survival. Outcomes included influenza vaccination, cholesterol screening, and colorectal cancer screening. Independent variables were number of physician visits, physician specialties visited, initial prostate cancer treatment, socio-demographic characteristics, and case–control status.

Results

There were 13,507 cases and 13,507 controls in Year 1, and 10,482 cases and 10,482 controls in Year 5. In Years 1 and 5, total number of visits (6/6 outcomes) and primary care provider (PCP) visits (5/6 outcomes) were most consistently associated with preventive care receipt. In Year 1, prostate cancer cases were more likely than controls to receive influenza vaccination (48% vs. 45%) but less likely to receive colorectal cancer screening (29% vs. 31%) (both p < 0.0001). In Year 5, prostate cancer cases remained more likely than controls to receive influenza vaccination (46% vs. 44%; p < 0.0001).

Conclusions

Differences in survivors’ short-term preventive care did not lead to worse long-term preventive care. The number of physician visits, particularly PCP visits, are important factors associated with appropriate care.
Implications for Cancer Survivors
PCP involvement in prostate cancer patients’ care is critical both during treatment and for long-term survivors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington: National Academy Press; 2005. Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington: National Academy Press; 2005.
2.
go back to reference Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors vs. controls: changes from 1998–2002. J Clin Oncol. 2009;27:1054–61.PubMedCrossRef Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors vs. controls: changes from 1998–2002. J Clin Oncol. 2009;27:1054–61.PubMedCrossRef
3.
go back to reference Snyder CF, Frick KD, Peairs KS, Kantsiper ME, Herbert RJ, Blackford AL, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24:469–74.PubMedCrossRef Snyder CF, Frick KD, Peairs KS, Kantsiper ME, Herbert RJ, Blackford AL, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009;24:469–74.PubMedCrossRef
4.
go back to reference Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–51.PubMedCrossRef Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–51.PubMedCrossRef
5.
go back to reference Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev. 2006;30:52–7.PubMedCrossRef Duffy CM, Clark MA, Allsworth JE. Health maintenance and screening in breast cancer survivors in the United States. Cancer Detect Prev. 2006;30:52–7.PubMedCrossRef
6.
go back to reference Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9.PubMedCrossRef Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9.PubMedCrossRef
7.
go back to reference Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med. 2008;23:254–9.PubMedCrossRef Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med. 2008;23:254–9.PubMedCrossRef
8.
go back to reference Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003;21:1161–6.PubMedCrossRef Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003;21:1161–6.PubMedCrossRef
9.
go back to reference Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–9.PubMedCrossRef Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101:1712–9.PubMedCrossRef
10.
go back to reference Yu X, McBean M, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. J Cancer Surviv. 2007;1:275–82.PubMedCrossRef Yu X, McBean M, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. J Cancer Surviv. 2007;1:275–82.PubMedCrossRef
11.
go back to reference American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2010. American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2010.
12.
go back to reference American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
16.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.PubMedCrossRef
17.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef
18.
go back to reference Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.PubMedCrossRef Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.PubMedCrossRef
19.
go back to reference Snyder CF, Frick KD, Blackford AL, Herbert RJ, Neville BA, Carducci MA, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010;116(23):5391–9.PubMedCrossRef Snyder CF, Frick KD, Blackford AL, Herbert RJ, Neville BA, Carducci MA, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010;116(23):5391–9.PubMedCrossRef
Metadata
Title
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors
Authors
Claire F. Snyder
Kevin D. Frick
Robert J. Herbert
Amanda L. Blackford
Bridget A. Neville
Michael A. Carducci
Craig C. Earle
Publication date
01-09-2011
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2011
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-011-0181-y

Other articles of this Issue 3/2011

Journal of Cancer Survivorship 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine